Cara Therapeutics reported $9.38M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 172.31M 174K Sep/2026
Alterity Therapeutics Limited AUD 10.88B 10.66B Dec/2025
Cara Therapeutics USD 9.38M 2.01K Mar/2026
Cassava Sciences USD 48.31M 0 Jun/2026
Chugai Pharma JPY 1.65B 0 Sep/2026
Cipla INR 807.87M 88K Sep/2026
Clal Biotechnology ILS 1.61M 0 Dec/2022
Compugen USD 94.72M 170K Jun/2026
CSL USD 482.13M 93.87M Dec/2025
Grifols EUR 680.58M 846.11K Dec/2025
Halozyme Therapeutics USD 113.94M 106K Sep/2026
J&J USD 2.41B 1.64M Jun/2026
Neurocrine Biosciences USD 101.3M 750K Sep/2026
Pacira USD 39.82M 512K Jun/2026
Pfizer USD 5.7B 0 Jun/2026
RedHill Biopharma USD 88.88B 37.95B Jun/2026
Supernus Pharmaceuticals USD 58.16M 124K Jun/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024